Scinai Immunotherapeutics Ltd. (SCNI)
NASDAQ: SCNI · Real-Time Price · USD
1.200
+0.130 (12.15%)
At close: Dec 5, 2025, 4:00 PM EST
1.150
-0.050 (-4.16%)
After-hours: Dec 5, 2025, 7:16 PM EST
Scinai Immunotherapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| TTM
| FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
| Jun '25 Jun 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
| Revenue | 1.15 | 0.66 | - | - | - | - | |
| Cost of Revenue | 2.83 | 1.24 | - | - | - | - | |
| Gross Profit | -1.69 | -0.58 | - | - | - | - | |
| Selling, General & Admin | 2.78 | 2.53 | 4.51 | 5.3 | 7.63 | 5.19 | |
| Research & Development | 3.98 | 5.53 | 5.21 | 5.77 | 3.25 | 16.01 | |
| Other Operating Expenses | - | - | -0.01 | - | -0.01 | -23.48 | |
| Operating Expenses | 6.76 | 8.06 | 9.71 | 11.06 | 10.86 | -2.28 | |
| Operating Income | -8.45 | -8.64 | -9.71 | -11.06 | -10.86 | 2.28 | |
| Interest Expense | -1.27 | -1.42 | -3.8 | - | - | -0.35 | |
| Interest & Investment Income | 0.1 | 0.1 | 3.92 | 3.05 | 3.15 | 0 | |
| Currency Exchange Gain (Loss) | -0.08 | -0.08 | -0.93 | 1.52 | -0.49 | 0.53 | |
| Other Non Operating Income (Expenses) | 0.08 | 0.08 | 4.02 | 0.69 | -0.01 | -3.85 | |
| EBT Excluding Unusual Items | -9.62 | -9.96 | -6.5 | -5.8 | -8.21 | -1.39 | |
| Other Unusual Items | 14.76 | 14.76 | - | - | - | - | |
| Pretax Income | 5.14 | 4.8 | -6.5 | -5.8 | -8.21 | -1.39 | |
| Net Income | 5.14 | 4.8 | -6.5 | -5.8 | -8.21 | -1.39 | |
| Preferred Dividends & Other Adjustments | 4.8 | 4.8 | - | - | - | - | |
| Net Income to Common | 0.35 | - | -6.5 | -5.8 | -8.21 | -1.39 | |
| Shares Outstanding (Basic) | 1 | 1 | 0 | 0 | 0 | 0 | |
| Shares Outstanding (Diluted) | 1 | 1 | 0 | 0 | 0 | 0 | |
| Shares Change (YoY) | 157.30% | 106.41% | 107.22% | 33.56% | 27.37% | 35.70% | |
| EPS (Basic) | 0.26 | - | -16.64 | -30.74 | -58.14 | -12.51 | |
| EPS (Diluted) | 0.26 | - | -16.64 | -30.74 | -80.00 | -12.51 | |
| Free Cash Flow | -5.71 | -6.35 | -10.02 | -8.1 | -7.57 | -24.47 | |
| Free Cash Flow Per Share | -4.33 | -7.87 | -25.65 | -42.97 | -53.60 | -220.83 | |
| Gross Margin | -146.99% | -88.15% | - | - | - | - | |
| Operating Margin | -736.36% | -1312.77% | - | - | - | - | |
| Free Cash Flow Margin | -497.38% | -964.59% | - | - | - | - | |
| EBITDA | -6.75 | -6.99 | -9.19 | -10.5 | -10.39 | 2.75 | |
| D&A For EBITDA | 1.7 | 1.65 | 0.51 | 0.56 | 0.47 | 0.47 | |
| EBIT | -8.45 | -8.64 | -9.71 | -11.06 | -10.86 | 2.28 | |
Source: S&P Capital IQ. Standard template.
Financial Sources.